2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2994

The Global Microrna Profile of Systemic Sclerosis Whole Skin/Dermal Fibroblasts and the Role of the Xq26.3 miRNA Cluster As a TGF-b Pathway Positive Feedback Mechanism

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2804

The Global miRNA Whole Blood Profile of Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 3011

The Homeoprotein Engrailed-1 Regulates Canonical TGF Beta Signaling in Experimental Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2480

The Impact of Emotional Trade-Off Difficulty on Choice

Psychology/Social Sciences (ARHP)

9:00AM-11:00AM: Abstract Number: 2302

The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2939

The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2654

The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2562

The Inhibition of Wnt/Beta-Catenin Signaling Pathway Via Paricalcitol and Pyrvinium Ameliorates Experimental Arthritis

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2902

The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2447

The Juvenile Arthritis Disease Activity Score Remains the Disease Activity Marker of Choice for Adults with Polyarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2711

The Lung Microbiome in Rheumatoid Arthritis and Associated Local/Systemic Autoimmunity

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2469

The Lymphocyte Repertoire in Juvenile Dermatomyositis

Pediatric Rheumatology - Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2894

The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2609

The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2560

The Mer Tyrosine Kinase Receptor Plays a Protective Role in Joint Inflammation By Mediating Efferocytosis

Rheumatoid Arthritis - Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].